Experienced biotechnology expert joins BRAIN Biotech AG's Supervisory Board EQS News: BRAIN Biotech AG / Key word(s): Personnel Experienced biotechnology expert joins BRAIN Biotech AG's Supervisory Board 23.07.2025 / 08:30 CET/CEST Responsible for the ...

Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG

 EQS News: BRAIN Biotech AG / Key word(s): Personnel
Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG

23.07.2025 / 08:30 CET/CEST
The issuer/publisher is responsible for the content of this announcement.

---------------------------------------------------------------------------

Experienced biotechnology expert joins the Supervisory Board of BRAIN Biotech AG

ZWINGENBERG, July 23, 2025 - The Supervisory Board of BRAIN Biotech AG is
fully staffed again: Dr. Ursula La Cognata was appointed by the District Court
Darmstadt with effect from 11 July 2025 until the next Annual General Meeting
as a new member of the Supervisory Board. With her
many years of biotechnology experience, the now complete
six-member committee.

Dr. Ursula La Cognata has held leading positions for many years for
Companies with a strong biotechnology focus, including Aventis
and Bayer and most recently with a focus on enzymes, fermentation
and natural foods. Dr. La Cognata currently leads her
own consulting company and supports innovative companies in
the market launch in the food sector and the development of
Production and fermentation capacities.

Chairman of the Supervisory Board Dr. Michael Majerus explains: "We have discussed with Ms.
Dr. Ursula La Cognata for our Supervisory Board a scientifically and
to recruit a highly competent and experienced biotechnologist
who, in addition to their extensive industry experience in connection with
Enzymes and fermentation processes, including their expertise in
product development and market launch of innovations.
We warmly welcome the new Supervisory Board member and are very pleased
on the constructive cooperation with her."

Adriaan Moelker, CEO of BRAIN Biotech AG, adds: "I am very pleased about
the extensive biotechnology expertise of our new Supervisory Board member. We
gain a lot of experience and networks in our
Target markets: nutrition, life sciences and the environment."

The judicial appointment of a new member to the Supervisory Board was
became necessary after a member of the Supervisory Board resigned from her mandate for personal reasons.
reasons.

+++

BRAIN Biotech Group

The BRAIN Biotech Group is a leading company in the research,
Development and production of special enzymes with a focus on
Food and life science industries. In addition, the
Group of microbial production organisms and scalable
Bioprocesses for the economical production of specialty enzymes and
other proteins. Tailor-made innovative biological solutions for
More sustainable products and processes complete the offering.

The parent company of the BRAIN Biotech Group is BRAIN Biotech AG.
The business activities of the integrated company are divided into
both segments BRAINBiocatalysts (development, production and distribution of
Special enzymes, microorganisms, ingredients) and BRAINBioIncubator
(research-intensive development projects, pharmaceuticals). For production
The Group operates fermentation plants in Great Britain and plants in
Continental Europe and the USA.

BRAIN Biotech has been listed on the Frankfurt Stock Exchange since February 9, 2016.
Stock Exchange (Ticker: BNN; ISIN DE0005203947 / WKN 520394).
The company employs around 300 people at several locations and
achieved sales of EUR 54.6 million in the 2023/24 financial year. Further
Information at: www.brain-biotech-group.com.

Contact Investor Relations

Martina Schuster
Investor Relations
Phone: +49 6251 9331-69
Email: [email protected]

Contact Media

Dr. Stephanie Konle
PR & Corporate Communications
Phone: +49 6251 9331-70
Email: [email protected]

The BRAIN Biotech Group on social media and online:

BRAIN Biotech Group

Web: www.brain-biotech-group.com

LinkedIn: https://www.linkedin.com/company/brainbiotech

Threads: https://www.threads.net/@brainbiotechag

Bluesky: https://bsky.app/profile/brain-biotech-group.com

X: https://x.com/BRAINbiotech

Youtube: https://www.youtube.com/channel/UCS33HJqku674X22UQ8QIsyg

Biocatalysts Ltd (production, distribution)

Website: https://www.biocatalysts.com/

LinkedIn: Biocatalysts Ltd on LinkedIn / BRAIN-Biocatalysts Life Science
Solutions on LinkedIn

BRAIN Biotech Zwingenberg (Technologies & Services)

Website: www.brain-biotech.com

LinkedIn: BRAIN Biotech Technologies & Services

AnalyticonDiscovery (Research & Development)

Web: https://ac-discovery.com/

LinkedIn: https://www.linkedin.com/company/analyticon-discovery/

Disclaimer

This press release contains forward-looking statements. These statements
reflect the current views, expectations and assumptions of the
Management of BRAIN Biotech AG and are based on information that
available to management at the present time.

Forward-looking statements do not contain any guarantee of
future results and developments and are subject to known and
unknown risks and uncertainties. The actual
future results of BRAIN Biotech AG and the BRAIN Biotech Group and
Developments concerning BRAIN Biotech AG and the BRAIN Biotech Group
can therefore differ significantly from the information provided here due to various factors.
expectations and assumptions expressed. These factors include
in particular changes in the general economic situation and the
competitive situation. In addition, developments in the
Financial markets and exchange rate fluctuations as well as national and international
Changes in the law, particularly with regard to tax regulations, as well as
other factors affect future results and
Developments by BRAIN Biotech AG.

BRAIN Biotech AG assumes no liability for the information contained in this
to update the statements contained therein.

Note: Collective terms used in this press release such as
Employees, shareholders, customers or consumers are considered gender-neutral
to watch.


---------------------------------------------------------------------------

23.07.2025 CET/CEST Publication of a corporate news/financial news,
transmitted by EQS News - a service of the EQS Group.
The issuer/publisher is responsible for the content of this announcement.

The EQS Distribution Services include statutory reporting obligations, corporate
News/financial news and press releases.
Media archive at https://eqs-news.com

---------------------------------------------------------------------------

Language: German
Company: BRAIN Biotech AG
Darmstadter Straße 34-36
64673 Zwingenberg
 Germany
 Telephone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
Email: [email protected]
 Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Stock exchanges: Regulated market in Frankfurt (Prime Standard);
Over-the-counter in Berlin, Düsseldorf, Hamburg, Munich,
 Stuttgart, Tradegate Exchange
EQS News ID: 2173240



End of message EQS News Service
---------------------------------------------------------------------------

2173240 23.07.2025 CET/CEST